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Abstract 
 
Background 
 
The genetic basis of left ventricular (LV) image-derived phenotypes, which play a vital role 
in the diagnosis, management and risk stratification of cardiovascular diseases, is unclear at 
present. 
 
Methods 
 
The LV parameters were measured from the cardiovascular magnetic resonance (CMR) 
studies of the UK Biobank. Genotyping was done using Affymetrix arrays, augmented by 
imputation. We performed genome-wide association studies (GWASs) of six LV traits – LV 
end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV stroke volume 
(LVSV), LV ejection fraction (LVEF), LV mass (LVM) and LV mass to end-diastolic 
volume ratio (LVMVR). The replication analysis was performed in Multi-Ethnic Study of 
Atherosclerosis (MESA). We identified the candidate genes at GWAS loci based on the 
evidence from extensive bioinformatic analyses. Polygenic risk scores (PRSs) were 
constructed from the GWAS summary statistics to predict the heart failure events. 
 
Results 
 
The study comprised 16,923 European UK Biobank participants (mean age: 62.5 years; 
45.8% men) without prevalent myocardial infarction or heart failure. We discovered fourteen 
genome-wide significant loci – three loci each for LVEDV, LVESV and LVMVR; four loci 
for LVEF and one locus for LVM – at a stringent p < 1 x 10-8. Three loci were replicated at 
Bonferroni significance and seven loci at nominal significance (P < 0.05 with concordant 
direction of effect) in the MESA study (N = 4,383). Follow-up bioinformatic analyses 
identified 28 candidate genes which were enriched in the cardiac developmental pathways 
and regulation of the LV contractile mechanism. Eight genes (TTN, BAG3, GRK5, HSPB7, 
MTSS1, ALPK3, NMB and MMP11) supported by at least two independent lines of in-silico 
evidence were implicated in the cardiac morphogenesis and heart failure development. The 
PRSs of LV phenotypes were predictive of heart failure in a hold-out UK Biobank sample of 
3,106 cases and 224,134 controls (odds ratio 1.41, 95% CI: 1.26 – 1.58, for the top quintile vs 
the bottom quintile of the LVESV risk score). 
 
Conclusions 
 
We report fourteen genetic loci and indicate several candidate genes which not only enhance 
our understanding of the genetic architecture of prognostically important LV phenotypes but 
also shed light on potential novel therapeutic targets for LV remodelling. 
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What is New? 
 
• Prognostically important left ventricular imaging phenotypes are highly heritable 
(~22% to 39%). 
• A total of fourteen genetic susceptibility loci (eight of which are unique) enriched in 
the cardiac developmental pathways and regulation of contractile mechanism, are 
discovered in the largest genome-wide association study of CMR-derived left 
ventricular phenotypes. 
• The polygenic risk scores of left ventricular phenotypes are predictive of heart failure 
events independently of clinical risk factors. 
 
What Are the Clinical Implications? 
 
• The findings from this study not only enhance our understanding of the genetic basis 
of prognostically important LV phenotypes in the general population but also 
underscore the intricate genetic relationship between these endophenotypes and the 
pathogenesis of the heart failure syndrome. 
• The prioritized genes in the genome-wide significant loci should be followed up in the 
functional studies to aid the development of potential novel therapies for heart failure.  
• The polygenic risk scores of left ventricular phenotypes may have a role in 
personalized risk stratification pending further validation of clinical robustness in 
future studies. 
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Introduction 
 
Heart failure is a clinically heterogeneous condition associated with a substantial mortality, 
morbidity and economic burden to the society1. Globally, both incidence and prevalence of 
heart failure are increasing due to improved survival from other contributory cardiovascular 
diseases in an ageing population. The diagnosis and treatment of heart failure is in part based 
on left ventricular (LV) functional and structural parameters derived from cardiac imaging. 
Although the impact of modifiable risk factors on LV structure and function is well 
established, our current understanding of the genetic component of these imaging phenotypes 
is limited. 
 
Previous large-scale genetic association studies of LV imaging phenotypes2,3 were hampered 
by the lack of a standardised measurement protocol in the phenotyping process and reliance 
on two-dimensional echocardiography (ECHO) with inherent dependency on geometric 
assumptions and adequate acoustic window. These shortcomings can be overcome by using 
the individual-level data from a single large study such as the UK Biobank, which also 
provides accurate and reproducible imaging phenotypes from cardiovascular magnetic 
resonance (CMR) imaging, considered to be a reference standard for the assessment of 
cardiac morphology4. 
 
Although multiple indices of LV structure and function can be measured from CMR images, 
five parameters – LV mass (LVM), LV end-diastolic volume (LVEDV), LV end-systolic 
volume (LVESV), LV stroke volume (LVSV) and LV ejection fraction (LVEF) – are 
frequently used in clinical practice and carry prognostic information5,6. In addition, LV mass 
to end-diastolic volume ratio (LVMVR) represents geometric remodelling of the left ventricle 
and an elevated LVMVR reflects concentric remodelling or hypertrophy associated with 
adverse outcomes7. Systematic genome-wide scanning for loci associated with the LV image-
derived measurements is a vital first step, which will advance our understanding of their 
genetic basis in a general population and may inform on novel diagnostic and targeted 
therapeutic opportunities. In this study, we conducted genome-wide association studies 
(GWASs) to identify the genetic loci for six clinically relevant CMR-derived LV imaging 
phenotypes. 
 
Methods 
 
Data access 
 
The data including GWAS summary statistics, analytic methods, and study materials will be 
returned to the UK Biobank. The UK Biobank will make these data available to all bona fide 
researchers for all types of health-related research that is in the public interest, without 
preferential or exclusive access for any person. Please see the UK Biobank’s website for the 
detailed access procedure (http://www.ukbiobank.ac.uk/register-apply/). 
 
UK Biobank 
 
The UK Biobank is a large population-based prospective cohort study of half a million 
people aged between 40-69 years at the time of initial recruitment between 2006 and 2010. It 
has collected a wealth of information on health and lifestyle data, physical measurements, 
biological samples, genotype and cardiac phenotypes derived from CMR. The study protocol 
has been described in detail previously8. The study complies with the Declaration of Helsinki 
and was approved by our institutional review body. All participants provided informed 
written consent. 
 
Genetic data 
 
Genotypes directly called by two closely-related, purpose-built arrays known as UK Biobank 
AxiomTM Array (825,927 markers) and UK BiLEVE AxiomTM Array (807,411 markers) were 
imputed to ~92 million variants using two reference panels (Supplemental Methods, UK 
Biobank genetic data).  
 
CMR phenotypes 
 
The detailed CMR protocol and analysis methods have been described previously9 and 
further details are available in Supplemental Methods, UK Biobank CMR phenotypes and 
Supplemental Figure 1. Since our primary aim was to investigate the genetic basis of LV 
image-derived phenotypes, we excluded individuals with prevalent myocardial infarction, 
heart failure or LVEF < 50% to minimise the confounding influence of these pre-existing 
conditions. Additional sample quality control measures were outlined in Supplemental 
Methods, Sample quality control and Supplemental Figure 2). 
 
Genetic analyses 
 
Primary analyses 
 
The detailed analysis strategy is outlined in Supplemental Methods, UK Biobank genetic 
association analysis and Supplemental Figure 3. We estimated the heritability explained by the 
genotyped variants (ℎ"# SNP) and bivariate genetic correlation (rg) using a variance component 
method implemented in BOLT-REML10. We next performed the discovery GWAS of each LV 
trait using a linear mixed-model method by BOLT-LMM11, under an additive genetic model 
with ~ 7 million imputed genetic variants with minor allele frequency (MAF) ³ 5% and 
imputation quality score (INFO) > 0.3. Both heritability analysis and GWAS models were 
adjusted for age, sex, height, weight, systolic blood pressure (SBP) corrected for anti-
hypertensive medication use (by adding 15mmHg), phenotype-derivation method 
(automatic/manual), array type (UK Biobank vs UK BiLEVE array), and imaging centre. (See 
Supplemental Methods, Definitions of covariates). The untransformed LV phenotypes which 
showed evidence of positive skewness normalised well after rank-based inverse normal 
transformation (INT) (Supplemental Figure 4). We used these INT phenotypes in all primary 
analysis models for heritability, genotypic correlation and GWAS. In addition to consideration 
for the multiple testing of genotype involved in a single GWAS, we had to consider multiple-
hypothesis testing with our six distinct, albeit correlated, LV traits. The effective number of 
phenotype-association tests estimated by Galwey method was 3.3. However, we set a more 
stringent threshold for genome-wide significance at p < 5 x 10-8/5 = 1 x 10-8 given the absence 
of a large replication cohort of comparable size. Genome-wide significant loci were defined by 
the most significant variant (known as the sentinel or lead variant) and their proxies (correlated 
variants) in linkage disequilibrium (LD) r2 > 0.1 in 1Mb region. 
 
We also performed conditional analysis to determine and the presence of secondary 
independent signals within the GWAS loci and nested linear regression analyses to calculate 
the percentage variance explained by the lead variants (Supplemental Methods, Conditional 
analysis and Percentage Variance). 
 
Secondary analyses 
 
As a sensitivity analysis, we adjusted the primary analysis models with additional 
cardiovascular risk factors, namely diastolic blood pressure (DBP) corrected for anti-
hypertensive medication use (by adding 10mmHg), body mass index (BMI) as a measure of 
obesity (replacing weight in the primary model to avoid collinearity), smoking status, regular 
alcohol use, dyslipidaemia and diabetes (See Supplemental Methods, Definitions of 
covariates). We also repeated the association analyses with untransformed LV traits while 
controlling for the same covariates as the primary analysis to obtain more comprehensible 
effect sizes (β) which are in the same unit of measurements as the LV traits (Supplemental 
Methods, Secondary analyses). Since the ratio of LV mass to LVEDV0.67 (concentricity0.67) 
was previously shown to be more correlated with both LV wall thickness and SBP than the 
standard definition of concentricity (LVMVR)12, we repeated the association analysis with 
this phenotype. Furthermore, potential mediating effects of SBP and sex were explored by 
incorporating the lead variant * covariate interaction terms in the primary models, using the 
mixed-model method implemented in the MMAP software (https://mmap.github.io/). 
Bonferroni correction was applied on the interaction p values to adjust for the number of 
variants tested. 
 
Replication analyses in the MESA cohort 
 
We performed the association analyses for all our sentinel variants in both European and non-
European ancestries of the Multi-Ethnic Study of Atherosclerosis (MESA)13. After sample 
quality control (See sample selection flowchart in Supplemental Figure 5), a total of 4,383 
individuals from MESA study (European = 1,742, African American = 1,083, Chinese = 586, 
Hispanic = 972) were included in the look-up analysis. Further details on the design and 
analysis of MESA cohort are available in Supplemental Methods. 
 
Pleiotropy analyses 
 
We searched PubMed to collate all genome-wide significant variants (p < 5x10-8) reported in 
published literature on closely related phenotypes (ECHO-derived LV measurements, left 
ventricular hypertrophy [LVH] identified by electrocardiogram [ECG]) and performed a 
lookup of these variants in our GWAS results. We cross-referenced our sentinel variants and 
their close proxies (LD r2 ³ 0.8 ) with Phenoscanner14 database v2 
(http://www.phenoscanner.medschl.cam.ac.uk/) and presented the variants which showed 
strong associations with other traits at p < 5x10-8. We also interrogated the GeneAtlas15 
database (http://geneatlas.roslin.ed.ac.uk/) to assess the associations of our variants with other 
traits in the UK Biobank. 
 
Functional annotation 
 
We employed an integrative bioinformatics approach to compile the functional information at 
both variant and gene level. Significant genomic loci were annotated using multiple lines of 
evidence including presence of coding variant, gene expression data, chromatin interaction 
analyses, knockout models and literature review (Supplemental methods, Bioinformatic 
annotation). 
 
Polygenic scoring 
 
We used the LDPred tool16 to construct the polygenic risk score (PRS) of each LV trait based 
on the effect sizes derived from the LV GWASs and predicted the risk of heart failure event 
in the remainder of the UK Biobank cohort. LDPred considers the tuning parameter known as 
the fraction of causal variant ($). In order to choose the best unbiased $, we first split the UK 
Biobank dataset into the training (2,033 cases; 149,461 controls) and test (3,106 cases; 
224,134 controls) sets. The final PRS constructed from the best-fit $ value was used to 
predict heart failure in the hold-out test dataset using a logistic regression model controlled 
for age, sex, BMI, SBP and DBP adjusted for anti-hypertensive medication use, smoking 
status, regular alcohol use, dyslipidaemia, diabetes, and 15 genetic principal components 
(PCs). We also explored the prospective association between LV-PRS quintiles and incident 
heart failure in the test dataset using multivariate Cox proportional hazards models adjusted 
for the same covariates as the logistic regression models. Further information on polygenic 
risk score is available in Supplemental Methods, Polygenic risk prediction of heart failure 
events. 
 
Results 
 
The overall study design is illustrated in Figure 1 and the summary characteristics of the UK 
Biobank CMR cohort are presented in Supplemental Table 1. The mean±SD age of the cohort 
62.5±7.5 years and 45.8% were men. The primary analysis comprised a total of 16,923 
European individuals with a maximum sample size of: LVEDV (n = 16,920), LVESV (n = 
16,920), LVSV (n = 16,917), LVEF (n = 16,923), LVM (n = 16,920) and LVMVR (n = 
16,884). Approximately 25% of the CMR studies were manually analysed and the remainder 
were segmented by a deep learning algorithm. The reproducibility of both manual and 
automatic measurements was very high (intra-class correlation coefficient ranged from 0.88 
to 0.98). 
 
Heritability and genotypic correlation 
 
The highest genome-wide heritability (h2g SNP) estimates were observed for the structural 
traits such as LVEDV and LVESV (both at 39%), followed by LVM at 34% and LVMVR at 
33% and the functional traits such as LVSV and LVEF had lower heritability (25% and 22%, 
respectively). The genotypic correlations between LV traits ranged from very high (rg = 0.92 
between LVEDV and LVSV) to very low (rg = -0.01 between LVSV and LVEF) (Figure 2).  
 
Genomic loci associated with LV phenotypes 
 
We discovered a total of fourteen genomic loci defined by a 1MB region – three loci each for 
LVEDV, LVESV and LVMVR; four loci for LVEF and one locus for LVM – at a stringent p 
< 1 x 10-8 as summarised in Table 1 and Figure 3. There was no evidence of population 
stratification or cryptic relatedness (genomic inflation factor, l = 1.047 – 1.097, quantile-
quantile plots in Supplemental Figure 6). We assigned a single “sentinel” variant with the 
lowest GWAS p value for each locus and plotted the LocusZoom plots for all sentinel 
variants (Supplemental Figure 7). Variants at several loci were associated with more than one 
LV trait. The TTN locus was associated with four LV traits (LVEDV, LVESV, LVEF, LVM), 
and the BAG3 and MTSS1 loci were shared across more than one trait (Figure 4). The LV 
remodelling trait, LVMVR, had three distinct loci (CDKN1A, DERL3 and ZNF592) which 
were not shared with other LV traits. No significant locus was found for LVSV. In total, eight 
unique loci were identified. There was no evidence of secondary independent variants 
achieving the pre-specified criteria at any loci in conditional analyses (Supplemental Table 
2). The percentages of trait variance explained by the sentinel variants were small as expected 
given the limited number of significant loci for each trait (LVEDV: 0.21%, LVESV: 0.32%, 
LVEF:0.38%, LVM: 0.10%, LVMVR: 0.46%). 
 
Secondary analyses 
 
The secondary analysis models additionally adjusted for other cardiovascular risk factors 
produced results generally congruous with the primary analyses, except for the SH2B3 locus 
for LVEDV where the GWAS p value of sentinel variant (rs7310615) became significantly 
attenuated (GWAS p secondary = 1.5x10-5, -log10 p primary/-log10 p secondary = 1.8; see 
Supplemental Table 3). The β estimates and the p values of our primary results and the 
analyses with untransformed LV phenotypes were highly correlated (ρ = 0.98 to 1.0 for β and 
ρ = 0.94 to 0.99 for p) with no significant attenuation of GWAS p values (-log10 p primary/-
log10 p secondary < 1.5) (Supplemental Table 4). The absolute effect sizes in the models 
with untransformed phenotypes ranged between 1 to 2ml for LVEDV and LVESV and 
~0.5% for LVEF per allele (Table 1). The lead variants for LVMVR loci remained genome-
wide significant (p < 1 x 10-8) in the sensitivity analyses with concentricity0.67 index. There 
was no significant interaction between SBP and the lead variants (Supplemental Table 5). In 
contrast, male sex significantly mediated the effects of lead variants in the TTN locus in the 
direction of larger LVEDV (interaction % = 2.63 ml per allele, p = 8.9 x 10-6) and LVESV 
(interaction % = 1.43 ml per allele, p = 9.3 x 10-6) and higher LVM (interaction % = 1.42 g per 
allele, p = 2.7 x 10-5) (Supplemental Table 6). 
 
Follow up of loci in an independent multi-ethnic cohort 
 
Out of fourteen locus-trait associations discovered in the UK Biobank, we validated three loci 
at Bonferroni significance (P < 0.0036 [0.05/14]) and seven loci at nominal significance (P < 
0.05 with concordant direction of effect) in at least one of the MESA ethnic sub-cohorts 
(summary characteristics in Supplemental Table 7). The rs200712209 variant associated with 
LVESV and rs34866937 variant associated with LVEF – both in MTSS1 locus – were 
replicated in the European subset of MESA study after Bonferroni correction. Three other 
variants tagging TTN, BAG3 and ZNF592 loci were nominally associated with LVESV, 
LVEF and LVMVR traits in the MESA European cohort (Supplemental Table 8).  
,  
Genetic relationships between CMR LV phenotypes with other related traits 
 
For ECHO traits, two previously reported variants in the SH2B3 and MTSS1 loci were 
genome-wide significant and four other variants were nominally significant (p < 0.05 with 
concordant directionality) for the corresponding CMR traits in our GWAS (Supplemental 
Table 9). The rs10774625 variant reported by Wild et al.2 for ECHO-derived LV end-
diastolic diameter (LVEDD) was in high LD (r2 = 0.95) with the sentinel variant at SH2B3 in 
our LVEDV GWAS. Previously unvalidated rs34866937 variant at the MTSS1 locus, 
reported by Kenai et al.3 for ECHO-derived LV end-systolic diameter (LVESD) and ECHO-
derived LVEF in a Japanese population was genome-wide significant for CMR-derived 
LVESV and LVEF in our European GWAS. For ECG-LVH traits, thirteen previously 
reported variants were nominally associated with our CMR-derived LVM (Supplemental 
Table 10). 
 
We also explored the association between our sentinel variants and their proxies with other 
traits from published GWASs using Phenoscanner14. The variants in the SH2B3 locus for 
LVEDV was associated with multiple risk factors which could mediate the cardiac 
remodelling process such as blood pressure/hypertension, cholesterol/LDL level, diabetes and 
smoking status. The variants in the CLCNKA and BAG3 loci for LVEF and LVESV were 
associated with dilated cardiomyopathy (DCM) (Supplemental Table 11). We also 
interrogated the Gene Atlas PheWAS database which reported the association results of 
hundreds of traits in the UK Biobank with our sentinel variants. The sentinel variant in the 
SH2B3 locus (rs7310615) was again found to be highly associated with the presence of 
hypertension (p = 5.9 x 10-46) and ischaemic heart disease (p = 4.8 x 10-14) in the UK Biobank 
(Supplemental Table 12). 
 
Functional annotation of variants 
 
At variant-level annotation, we identified a total 238 candidate variants for all LV traits 
(7.6% exonic variants, 45% intronic variants, 30% intergenic variants; see Supplemental 
Figure 8). Out of 18 exonic variants, 12 were nonsynonymous and were located in the BAG3, 
ALPK3, TTN, SH2B3, NMB and WDR73 genes. The missense variant, rs2234962, in the 
BAG3 gene for LVESV and LVEF was predicted to be damaging by at least two prediction 
tools. 
 
Among 220 non-coding variants, 52 were located in promotor histone marks, 148 in enhancer 
histone marks, 82 in DNase I sites and 13 altered the binding sites of regulatory proteins. We 
also found 6 non-coding variants which were highly conserved in vertebrates according to 
SiPhy17. RegulomeDB18 ranked three non-coding variants in the ZNF592 locus as class 1f 
(strong support for functional importance). Of these variants, two (rs2175567 and 
rs17598603) were intronic for the NMB gene and the other (rs7237) was located in the 3’ 
UTR region of the WDR73 gene. The expression quantitative trait locus (eQTL) analysis in 
Genotype-Tissue Expression (GTEx) dataset19 revealed that rs35006907, a close proxy of the 
sentinel variants in the MTSS1 locus for LVESV and LVEF, was associated at false discovery 
rate (FDR) < 0.05 with the MTSS1 gene expression in left ventricle and left atrial appendage 
tissues. Additionally, rs2070458, a proxy variant in the DERL3 locus for LVMVR was 
associated with the MMP11 gene expression in left ventricular tissue (Supplemental Table 
13).  
 
We explored the long-range interaction influence of the sentinel variants and their proxies in 
the Hi-C data of aorta, left ventricle and right ventricle and found 11 potential target genes 
(Supplemental Table 14). A summary of all variant-level annotations is presented in 
Supplemental Table 15. The gene prioritisation, gene-set enrichment and pathway analyses 
for the LV traits did not yield any significant results. However, in the tissue-specific 
enrichment analysis using the data from the Roadmap Epigenomics project, there was a 
significant enrichment of our genome-wide significant LV variants within the regions of 
DNase I hotspots in foetal heart tissue (Supplemental Figure 9).  
 
At gene-level annotation, we identified a total of 28 candidate genes at eight unique loci: five 
genes were prioritised by presence of nonsynonymous variant (sentinel or proxies with LD r2 
³ 0.8), six were prioritised by eQTL data in cardiovascular tissues, 11 were prioritised based 
on long-range chromatin interactional analyses and six were prioritised by availability of 
knockout models (Supplemental Table 16). A summary of prioritised genes for all LV traits 
is depicted in Figure 5. Evaluation of these genes as input in GeneNetwork20 pathway 
analysis revealed enrichment for terms related to “heart development”, “regulation of the 
force of heart contraction” and “abnormality of the cardiovascular system” (Supplemental 
Table 17). 
 
Polygenic risk score analyses 
 
We explored the predictive ability of polygenic risk scores (PRSs) derived from the genetic 
variants associated with LV traits to predict heart failure events in an independent test sample 
of the UK Biobank cohort (3,106 cases, 224,134 controls). All LV-PRSs (except LVM-PRS) 
were significantly associated with heart failure. The PRS quintiles of LVEDV and LVESV 
were associated with higher odds of heart failure (OR: 1.25 – 1.41 for the top 20% vs bottom 
20% group) while the opposing pattern was observed for LVEF- and LVMVR-PRSs across 
all levels of adjustments for potential confounders including age, sex, body size and 
cardiovascular risk factors (Table 2). The sensitivity analyses including only incident cases 
produced similar patterns of association between LV-PRS quintiles and incidence of heart 
failure (Supplemental Figure 10). 
 
Discussion 
 
This is the largest individual-level genome-wide association study to date investigating the 
genetic architecture of prognostically important LV phenotypes derived from CMR. The key 
strength of this study is the combination of standardised, highly precise and reproducible 
phenotyping process with a high-quality dense genotype dataset in a cohort of ~ 17,000 
individuals free from myocardial infarction and heart failure. This strategy yielded a total of 
fourteen locus-trait associations. Three loci (TTN, BAG3 and MTSS1) were shared between 
more than one LV trait resulting in the discovery of eight unique loci, of which six were 
novel for LV imaging traits. The follow-up analysis of our sentinel variants in an independent 
multi-ethnic cohort (MESA) showed a strong support for two loci (MTSS1 and BAG3) at the 
level of Bonferroni-significance while three other loci (TTN, SH2B3 and ZNF592) achieved a 
nominal support. Our enrichment analyses revealed that the regulatory variants associated 
with the LV loci are highly enriched in the foetal heart tissue and the candidate genes for 
these loci are involved in the cardiac developmental pathways and regulation of the LV 
contractile mechanism. 
 
Although the LV image-derived phenotypes were known to be heritable, their reported 
heritability varied widely, ranging from 15%21 to 84%22 for LVM, which may reflect the 
methods used including monozygotic and dizygotic twins, siblings, nuclear and complex 
families. In this study, we provide a robust estimate of the proportion of LV phenotypic 
variance explained by the genotype (h2g SNP heritability) in a large population of unrelated 
Caucasian individuals. A significant proportion of LV phenotypic variability was explained 
by the genotype (ranging from 22% to 39%) and the structural traits such as LVEDV or LVM 
had a noticeably higher heritability than more functional traits such as LVEF. The relatively 
lower heritability estimates in these functional traits could be due to the inflated inter-
personal variations secondary to differences in the loading conditions and chronotropic and 
inotropic states23. The heritability estimates of CMR-derived LV traits were overall higher 
than previously reported values in other complex cardiovascular traits such as resting heart 
rate (h2g = 21%)24 and comparable ECHO traits (for example, LVM h2g = 14.8% for ECHO 
vs. 39% for CMR)3. However, the heritability of the ECHO trait was calculated using the 
summary-level data with LD score regression approach, which tends to produce lower 
estimates than the variance component method (which requires the individual-level data) as 
in our study. The pattern and magnitude of genotypic correlations between LV traits mostly 
mirrored the corresponding phenotypic correlations except for the relationship between 
LVSV and LVEF, where the genotypic correlation was absent despite a moderate phenotypic 
correlation (rp = 0.39 vs rg = -0.01). The finding may suggest dissimilar genetic architecture 
between these two functional traits which should be validated in an independent cohort. The 
majority of genomic loci observed in our study were specific for the LV traits except for the 
SH2B3 locus (associated with LVEDV) which appeared to be highly pleiotropic and 
associated with multiple cardiovascular risk factors. This finding may explain the substantial 
weakening of the sentinel variant’s association p value in our secondary analysis additionally 
adjusted for a wider range of cardiovascular risk factors. 
  
Among several candidate genes, we highlighted the functional roles of a few potential causal 
genes based on the bioinformatic analyses and literature review. The TTN (titin) gene 
emerged as a strong candidate causal gene for four LV traits (LVEDV, LVESV, LVEF and 
LVM). The pivotal function of TTN in the maintenance of sarcomere assembly, stretch 
sensing and signalling, passive stiffness adjustment and active force generation25 corresponds 
well with our finding of TTN being an important gene for both structural and functional LV 
imaging traits. Several titin-truncating variants (TTNtv) have been found in 10% to 20% of 
DCM cases and may have a role in the pathogenesis of DCM in these individuals26. These 
TTNtv have been reported to occur at much lower frequencies in the general population 
(1.1% of alleles in the 1000 Genomes project)27 and were found to be associated with larger 
LV volumes28. In our study including variants with minor allele frequency ³ 5%, we found 
several missense variants (but no protein truncation variants) in the TTN locus (Supplemental 
Table 13) which were all predicted to be benign by the pathogenicity prediction tools. 
 
The BAG3 (BCL2 associated athanogene 3) gene appears to be a likely candidate gene which 
is involved in modulation of the two volumetric traits (LVEDV and LVESV) and the derived 
LV functional index (LVEF). BAG3 encodes an anti-apoptotic protein expressed in the heart 
and skeletal muscle and serves as a co-chaperone of heat-shock protein (HSP) family29. It is 
essential for the homeostasis of filamin30 and influences myocyte contraction through 
interaction with the b1-adrenegic receptor and the L-type calcium channel31. Mutations in 
BAG3 gene have been implicated in DCM pathogenesis with the myocardial tissues 
displaying evidence of myofibril disarray and relocation of BAG3 protein in the sarcomeric 
Z-disc32. In our cohort of individuals with preserved LVEF, free from known heart failure or 
DCM, we found a missense mutation (rs2234962, LD r2 0.99 with the sentinel variant) in the 
BAG3 gene which was reported to be damaging by two in-silico prediction tools. The same 
missense variant has been indicated as the sentinel variant in a DCM GWAS33, underlining 
the shared genetic basis of LV volumetric phenotypes and DCM. Our long-range chromatin 
interaction (Hi-C) analysis flagged up another potential candidate gene at the BAG locus 
called GRK5 (G Protein-Coupled Receptor Kinase 5) gene. GRK5 regulates cardiac 
development through the mTOR pathway in Zebrafish34,35. Its expression level in the 
myocardium is elevated in heart failure36 and a non-synonymous polymorphism of GRK5 
appears to be protective of heart failure through inhibition of β-Adrenergic receptor 
signalling37. In addition, GRK5 is a known drug target for β-blockers and anti-hypertensive 
agents (Supplemental Table 14). At the CLCNKA locus for LVEF, we indicate HSPB7 (Heat 
Shock Protein Family B Member 7) as a likely candidate given its recognised role in 
cardiogenesis by modulating actin filament assembly38,39 and known association with heart 
failure development40. Decreased cardiomyocyte proliferation and abnormal sarcomere 
morphology were observed in HSPB7 knockout mice. 
 
The MTSS1 locus for CMR-derived LVESV and LVEF has previously been reported for 
comparable ECHO-derived LV traits2,3. The sentinel variant at the MTSS1 locus is in the 
intergenic region. However, its close proxy (rs35006907, r2 > 0.98) is located in the DNase I 
hypersensitive site in the cardiac tissue and is associated with expression of the MTSS1 
(Metastasis Suppressor Protein 1) gene in left ventricular and left atrial appendage tissues. 
This gene is involved in cytoskeletal signalling pathway41 and encodes a scaffold protein that 
regulates actin dynamics42. 
 
The GWAS of remodelling phenotype, LVMVR, produced three genetic loci which were not 
shared with other LV traits. The ALPK3 (Alpha Kinase 3) gene in the ZNF592 locus is 
expressed in the developing heart and involves in cardiomyocyte differentiation43. The 
ALPK3 knockout mouse model exhibited evidence of cardiac-specific phenotypic changes 
such as LV dilatation and hypertrophy. Another potential candidate gene at the same locus is 
NMB (Neuromedin B) gene which is associated with regulation of eating behaviour and 
obesity44. This gene has previously been highlighted as a candidate gene in a GWAS 
investigating the ECG indices of LV hypertrophy45, in which the sentinel variant was 
moderately correlated (LD r2 0.39) with our LVMVR sentinel variant. Lastly, the proxy 
variant (rs2070458) of the DERL3 locus for LVMVR was in cis-eQTL with the MMP11 
(Matrix Metallopeptidase 11) gene expression in left ventricle. MMP11 belongs to the family 
of proteolytic enzymes that regulate extracellular matrix and play a role in the development 
of myocardial fibrosis and ventricular remodelling46,47. 
 Altogether, several key candidate genes in our GWAS loci (such as TTN, BAG3, MTSS1) 
which were shared across multiple structural and functional LV traits, encode essential 
proteins involved in the construction and maintenance of sarcomeric infrastructure. In 
contrast, the variation of LVMVR, the LV remodelling trait, was determined by the genetic 
loci containing candidate genes implicated in cardiomyocyte differentiation and extracellular 
matrix homeostasis. 
 
Despite a limited number of loci found in this study, the polygenic risk scores (PRSs) 
constructed from LVEDV, LVESV, LVEF and LVMVR were predictive of heart failure 
events in the remainder of the UK Biobank cohort. This finding reinforces the fundamental 
role of the LV imaging endo-phenotypes in the pathogenesis of heart failure. The 
directionality of association between PRSs and heart failure event was generally concordant 
with prior expectations (alleles associated with larger LVEDV and LVESV and lower LVEF 
were predictive of increased risk of heart failure) except for the PRS derived from LVMVR 
where higher scores were correlated with lower odds of heart failure. LVMVR is a geometric 
phenotype where higher values are indicative of concentric remodelling or concentric 
hypertrophy of left ventricle. Despite the conventional wisdom of higher LVMVR being 
associated with an increased risk of adverse cardiovascular outcomes, a prospective 
longitudinal study in general population did not find a positive correlation between LVMVR 
and heart failure events7. Furthermore, previous studies have reported that LV concentricity 
indicated by an increased LVMVR did not commonly lead to impaired LVEF especially in 
the absence of interval myocardial infarction48,49. The significant negative association 
between LVMVR-PRS and heart failure in this study may reflect the possible dominance of 
dilatative (rather than hypertrophic) phenotype in the heart failure cases in our cohort. 
Interestingly and contrary to the epidemiological evidence of association between LVM and 
incident heart failure7,50, the LVM-PRS was not predictive of heart failure in our study. 
Although LVM appeared to be highly heritable in our genome-wide heritability analysis (h2g 
SNP = 34%), only a single locus was discovered at p < 1x10-8 (percentage variance explained 
= 0.1%). Thus, the limited statistical power may have curtailed the predictive ability of LVM-
PRS. 
 
We acknowledge some limitations in our study. Despite being the largest GWAS of CMR 
image-derived LV phenotypes, the relatively small discovery sample size translated to the 
discovery of a few loci explaining < 0.5% of trait variance per trait. Additionally, the current 
sample size restricted our analysis to common variants with MAF ³ 5%. However, the 
expected expansion of the CMR sample size to 100,000 in the UK Biobank, together with the 
highly optimised automatic image segmentation pipeline will lead to future studies with 
statistical power to detect more genetic loci at a lower MAF threshold. Furthermore, the 
upcoming exome sequencing data from the UK Biobank may allow us to investigate the role 
of rarer, protein truncating variants in a general population. Of note, three out of eight unique 
loci discovered in the UK Biobank were not replicated in MESA. Therefore, the evidence for 
these susceptibility loci should be considered preliminary. Second, although we have 
performed a limited look-up of our loci in MESA for additional support, our findings should 
be formally validated in a larger cohort. 
 
In summary, the findings from this study not only enhance our understanding of the genetic 
basis of prognostically important LV phenotypes in the general population but also 
underscore the intricate genetic relationship between these endophenotypes and the 
pathogenesis of heart failure syndrome, which may lead to potential novel therapeutic targets 
and personalised risk stratification strategy in the future.  
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Figure titles and legends 
Figure 1. Flowchart of analysis strategy 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVSV, left ventricular stroke volume; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ratio; LVEF, left ventricular ejection fraction; SBP, systolic 
blood pressure; REML, restricted maximal likelihood; SNV, single nucleotide variant; MAF, 
minor allele frequency; INFO, imputation quality score; LD, linkage disequilibrium; GCTA, 
genome-wide complex trait analysis; MESA, multi-ethnic study of atherosclerosis 
 
Figure 2. SNP-heritability and genotypic and phenotypic correlations between LV traits 
The upper triangle of correlogram represents the degree of genotypic correlation and the 
lower triangle represents the degree of phenotypic correlation. Heritability estimated from 
genotyped SNPs is presented on the right-hand side of the figure. * p < 0.0001; # p > 0.05; All 
other correlation estimates had p < 1x10-16 
SNP, single nucleotide polymorphism; LVEDV, left ventricular end-diastolic volume; 
LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVM, 
left ventricular mass; LVMVR, left ventricular mass to end-diastolic volume ratio; LVEF, left 
ventricular ejection fraction; SD, standard deviation 
 
Figure 3. Genomic loci associated with CMR-LV phenotypes 
Circular Manhattan plot depicting the GWAS results of all LV traits. The red line indicates 
the genome-wide significant threshold at p < 1x10-8. No genome-wide significant locus was 
found for LVSV. The significant genomic loci are denoted by the red dots. 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVSV, left ventricular stroke volume; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ratio; LVEF, left ventricular ejection fraction 
 
Figure 4. Venn diagram of LV loci 
The locus name indicates the nearest annotated gene. 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVM, left ventricular mass; LVMVR, left ventricular mass to end-diastolic volume ratio; 
LVEF, left ventricular ejection fraction 
 
Figure 5. Summary of genes associated with LV traits 
Genes are ranked on the basis of the supporting evidence summarised in Supplemental Table 
11 based on the presence of nonsynonymous variant, gene expression data, chromatin 
interaction analyses, literature review and knockout models.  
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ration 
* coding variant gene, † knockout phenotype, ‡ Previously reported cardiovascular biology or 
strong functional rationale, § expression quantitative trait locus (eQTL) gene, || Hi-C long-
range interaction gene 
The illustration used elements with permission from Servier Medical Art. 
 
 
 
 
Table 1. Genomic loci identified for CMR-derived LV phenotypes  
 
CMR 
trait 
Locus 
Name Lead variant CHR 
Position 
(hg19) EA NEA EAF 
BETA 
INT SE INT 
P 
INT 
BETA  
raw 
SE 
raw 
LVEDV TTN rs2042995† 2 179558366 T C 0.779 0.087 0.013 2.3E-11 1.956 0.295 
LVEDV BAG3 rs7071853 10 121311606 T C 0.767 -0.075 0.013 3.9E-09 -1.672 0.289 
LVEDV SH2B3 rs7310615† 12 111865049 C G 0.481 -0.066 0.011 1.4E-09 -1.409 0.247 
LVESV TTN rs2042995† 2 179558366 T C 0.779 0.118 0.013 8.4E-20 1.431 0.161 
LVESV MTSS1 rs200712209* 8 125858538 GA G 0.687 0.079 0.012 1.7E-11 0.953 0.145 
LVESV BAG3 rs72840788† 10 121415685 G A 0.778 0.109 0.013 5.6E-17 1.352 0.162 
LVEF CLCNKA rs945425 1 16348412 T C 0.326 0.075 0.011 8.6E-11 0.368 0.057 
LVEF TTN rs2042995† 2 179558366 T C 0.779 -0.091 0.013 2.5E-12 -0.446 0.064 
LVEF MTSS1 rs34866937* 8 125859850 G A 0.686 -0.076 0.012 6.8E-11 -0.379 0.058 
LVEF BAG3 rs72840788* 10 121415685 G A 0.778 -0.104 0.013 3.4E-15 -0.507 0.065 
LVM TTN rs2255167† 2 179558282 T A 0.812 0.103 0.014 8.3E-14 1.246 0.168 
LVMVR CDKN1A rs146170154 6 36646768 C CTA 0.802 -0.092 0.014 2.6E-11 -0.007 0.001 
LVMVR ZNF592 rs149369954† 15 85348961 TTTTG T 0.745 0.085 0.013 1.9E-11 0.006 0.001 
LVMVR DERL3 rs6003909 22 24181652 A G 0.172 0.111 0.014 9.7E-15 0.008 0.001 
The novel loci are highlighted in bold face. The locus name indicates the nearest annotated gene. The p values were calculated from the BOLT-
LMM !2 tests statistics obtained from the linear mixed-effects models adjusted for age, sex, height, weight, systolic blood pressure corrected for 
anti-hypertensive medication use, phenotype-derivation method (automatic/manual), array type (UK Biobank vs UK BiLEVE array), and 
imaging centre. The sample size for each phenotype are: LVEDV (n = 16,920), LVESV (n = 16,920), LVSV (n = 16,917), LVEF (n = 16,923), 
LVM (n = 16,920) and LVMVR (n = 16,884).  
CMR, cardiovascular magnetic resonance; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, 
left ventricular ejection fraction; LVM, left ventricular mass; LVMVR, left ventricular mass to end-diastolic volume ratio; CHR, chromosome; 
EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency in UKBB cohort; SE, standard error; INT, rank-based inverse normal 
transformation 
* Support in MESA cohort at p < 0.0036 [Bonferroni-correction=0.05/14]; † Nominal Support in MESA cohort at p < 0.05 with concordant 
direction of effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Polygenic risk prediction of heart failure using PRSs constructed from 
variants associated with LV traits 
 
Phenotype (mean ± SD) PRS quintiles OR (95% CI) P 
LVEDV (126 ± 23 ml) Q1 (Reference) 1 – 
LVEDV (136 ± 24 ml) Q2 1.07 (0.95-1.20) 2.74E-01 
LVEDV (144 ± 26 ml) Q3 1.16 (1.04-1.31) 1.05E-02 
LVEDV (153 ± 27 ml) Q4 1.19 (1.06-1.34) 3.53E-03 
LVEDV (177 ± 35 ml) Q5 1.25 (1.11-1.40) 1.49E-04 
LVESV (47 ± 11 ml) Q1 (Reference) 1 – 
LVESV (53 ± 12 ml) Q2 1.13 (1.004-1.28) 4.32E-02 
LVESV (57 ± 13 ml) Q3 1.16 (1.03-1.31) 1.50E-02 
LVESV (63 ± 14 ml) Q4 1.21 (1.08-1.36) 1.60E-03 
LVESV (75 ± 17 ml) Q5 1.41 (1.26-1.58) 4.76E-09 
LVEF (56 ± 4 %) Q1 (Reference) 1 – 
LVEF (58 ± 4 %) Q2 0.88 (0.78-0.98) 1.95E-02 
LVEF (60 ± 4 %) Q3 0.84 (0.75-0.94) 1.82E-03 
LVEF (62 ± 4 %) Q4 0.85 (0.76-0.95) 3.17E-03 
LVEF (65 ± 4 %) Q5 0.77 (0.69-0.86) 6.64E-06 
LVM (78 ± 17 g) Q1 (Reference) 1 – 
LVM (80 ± 19 g) Q2 0.96 (0.86-1.08) 5.19E-01 
LVM (83 ± 20 g) Q3 0.96 (0.86-1.08) 5.23E-01 
LVM (87 ± 21 g) Q4 0.90 (0.80-1.01) 7.37E-02 
LVM (99 ± 26 g) Q5 1.06 (0.94-1.18) 3.48E-01 
LVMVR (0.51 ± 0.06 g/ml) Q1 (Reference) 1 – 
LVMVR (0.55 ± 0.06 g/ml) Q2 1.05 (0.94-1.17) 3.93E-01 
LVMVR (0.58 ± 0.06 g/ml) Q3 0.93 (0.83-1.04) 2.14E-01 
LVMVR (0.61 ± 0.07 g/ml) Q4 0.90 (0.80-1.01) 6.23E-02 
LVMVR (0.67 ± 0.09 g/ml) Q5 0.80 (0.71-0.90) 2.66E-04 
 
The association between the polygenic risk scores calculated from the summary statistics of 
LV GWASs and heart failure development was estimated by logistic regression in the hold-
out test sample of UK Biobank cohort (Total N = 227,240 [3,106 cases, 224,134 controls]). 
The PRS models were adjusted for age, sex, BMI, SBP and DBP corrected for anti-
hypertensive medication use, smoking status, regular alcohol use, dyslipidaemia, diabetes and 
15 PCs.  
The mean± SD of each LV phenotype for each PRS quintile is presented in the parenthesis. 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ratio; PRS, polygenic risk score; SD, standard deviation; OR, 
odds ratio; CI, confidence interval; PCs, genetic principal components 
 
Figure 1. Flowchart of analysis strategy 
 
 
 
Genome-wide association studies of 6 LV phenotypes 
(LVEDV, LVESV, LVSV, LVM, LVMVR, LVEF)
Primary analysis in UK Biobank European cohort (Nmax = 16,923)
1. Inverse-normal rank transformation (IVNT) of LV traits after adjusting for age, sex, height, weight, 
medication-adjusted SBP, phenotype-derivation method (automatic/manual), array type (UK Biobank vs UK 
BiLEVE array), and imaging centre
2. Heritability and genetic correlation analyses of IVNT-LV traits using BOLT-REML algorithm
3. GWASs: IVNT-LV phenotypes ~ SNV with MAF ≥ 5% and INFO > 0.3
4. Loci assignment: Sentinel variants (p < 1x10-8) + proxies (LD r2 > 0.1 in 1-Mb region)
14 locus-trait pairs – LVEDV (3), LVESV (3), LVSV (0), 
LVEF (4), LVM (1), LVMVR (3)
(3 shared loci across multiple traits → 8 unique loci)
• Conditional analysis in GCTA
• Secondary analyses with: (i) 
additional adjustment of 
covariates and (ii) untransformed 
phenotypes
• Look-up of sentinel variants for
support in MESA
• Polygenic risk score analysis
Bioinformatic analyses
• Coding and regulatory annotation
• Gene expression analysis
• Enrichment analysis
• Trait pleiotropy analysis
28 candidate genes (8 potential causal genes with ≥ 2 lines of evidence)
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVSV, left ventricular stroke volume; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ratio; LVEF, left ventricular ejection fraction; SBP, systolic 
blood pressure; REML, restricted maximal likelihood; SNV, single nucleotide variant; MAF, 
minor allelic frequency; INFO, imputation quality score; LD, linkage disequilibrium; GCTA, 
genome-wide complex trait analysis; MESA, multi-ethnic study of atherosclerosis 
 
 
 
Figure 2. SNP-heritability and genotypic and phenotypic correlations between LV traits 
 
 
 
The upper triangle of correlogram represents the degree of genotypic correlation and the 
lower triangle represents the degree of phenotypic correlation. Heritability estimated from 
genotyped SNPs is presented on the right-hand side of the figure. * p < 0.0001; # p > 0.05; All 
other correlation estimates had p < 1x10-16 
SNP, single nucleotide polymorphism; LVEDV, left ventricular end-diastolic volume; 
LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVM, 
left ventricular mass; LVMVR, left ventricular mass to end-diastolic volume ratio; LVEF, left 
ventricular ejection fraction; SD, standard deviation 
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Figure 3. Genomic loci associated with CMR-LV phenotypes 
 
 
 
 
LVEDV
LVESV
LVSV
LVEF
LVM
LVMVR
Circular Manhattan plot depicting the GWAS results of all LV traits. The red line indicates 
the genome-wide significant threshold at p < 1x10-8. No genome-wide significant locus was 
found for LVSV. The significant genomic loci are denoted by the red dots. 
 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVSV, left ventricular stroke volume; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ratio; LVEF, left ventricular ejection fraction 
 
 
 
Figure 4. Venn diagram of LV loci 
 
 
 
The locus name indicates the nearest annotated gene. 
 
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVM, left ventricular mass; LVMVR, left ventricular mass to end-diastolic volume ratio; 
LVEF, left ventricular ejection fraction 
 
 
 
 
 
 
 
Figure 5. Summary of genes associated with LV traits 
 
 
 
 
Genes are ranked on the basis of the supporting evidence summarised in Supplemental Table 
11 based on the presence of nonsynonymous variant, gene expression data, chromatin 
interaction analyses, literature review and knockout models.  
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMVR, left ventricular 
mass to end-diastolic volume ration 
b Previously reported cardiovascular biology or strong functional rationale, c coding variant 
gene, e expression quantitative trait locus (eQTL) gene, h Hi-C long-range interaction gene, k 
knockout phenotype 
The illustration used elements with permission from Servier Medical Art. 
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